Abstract:Rationale: To ensure that quality medicines are available to the populace. Aim and objective: To provide a new perspective for drug sampling and testing using a risk-based approach globally, and provide a reference for improving the efficiency of the drug sampling and testing programme in China. Method: This study used a combination of theoretical analysis and problem analysis. First, we analysed the high-risk drugs that should be given attention to theoretically in the drug sampling testing programme based on the healthcare reform in China. Second, this study leveraged on data on the sampling and testing of drugs extracted from self-constructed data by the China Food and Drug Administration (CFDA). The integrated and structured data sets were used to conduct an innovative analysis that identifies the actual content of the drug sampling and testing programme and contrasts them with the theoretical content to understand the problems. This study used quantitative and qualitative approaches for data analysis. Results: Following analysis, we discovered that there is still a big gap between the reality of drug sampling and testing in China and the ideal state of the objective requirements of healthcare reforms. The major sources of risk are the retail pharmacies or hospital pharmacies in the distribution chain of drugs; however, the CFDA sampled mostly drugs from drug manufacturers. Additionally, the CFDA did not sample adequate essential medicines, bid-winning drugs (especially those with large price drops in centralized procurement), biological products and other high-risk drug varieties. The high-risk drugs produced by companies or enterprises with a history of noncompliance, especially bid-winning enterprises in centralized procurement, were not sampled. Conclusion: We suggest that the major content of drug sampling and testing in China should focus on the link of drug utilization, varieties of drugs with large price drops in centralized procurement and bid-winning enterprises with a history of noncompliance.

Analysis of the Implementation Status of Zero Slip Policy of Essential Drugs in Basic Medical and Health Institutions

Zero mark-up policy of essential medicines system in China:Problems and recommendations

Essential medicines system reform in China:Achievements and challenges

An Analysis of China's National Essential Medicines Policy

Ningbo Pilot Implementation Status Quo of National Essential Medicine System and Countermeasures

Essential medicine policy in China: pros and cons.

Preliminary analysis of pharmaceuticals zero mark-up policy in Shanghai

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

Study on the Implementation of Essential Medicine Policy in Primary Care Institutions in Shaanxi Province

An Analysis on Rational Use and Affordability of Medicine after the Implementation of National Essential Medicines Policy and Zero Mark-up Policy in Hangzhou, China

Intended and Unintended Consequences of China’s Zero Markup Drug Policy

Important concerns and actions in the implementation of essential medicine system in Shanghai

Investigation and Survey of Essential Drugs Provision and Use in Primary Health Care Institutions from Some Areas in China

Strategies and policy recommendations on improving essential medicines system in China

Evidence-based Research on the Selection Method System for China's Essential Medicine List

Evaluation of Effect of Zero-Profit Drugs Policy in a Community Healthcare Service Center

The zero profit drug policy brings opportunities and challenges for pharmacy development transition of public hospitals

The study on zero profit drug supply and the corresponding reimbursement policy in medical institutions in Shanghai

Original Article Essential Medicine Policy in China: Pros and Cons

Analysis on drug application in village health posts in poor rural area of western China

Reform of the Essential Drugs Supply Mode in One District,shanghai